Company Encyclopedia
View More
name
Uniqure
QURE.US
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington’s disease.
1.946 T
QURE.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
E
BiotechnologyIndustry
Industry Ranking364/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-165.27%E
    • Profit Margin-1492.90%E
    • Gross Margin-771.31%E
  • Growth ScoreD
    • Revenue YoY-44.90%E
    • Net Profit YoY1.82%C
    • Total Assets YoY37.56%A
    • Net Assets YoY309.78%A
  • Cash ScoreD
    • Cash Flow Margin-6.70%D
    • OCF YoY-44.90%E
  • Operating ScoreE
    • Turnover0.02E
  • Debt ScoreE
    • Gearing Ratio74.25%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    16:48 ET QURE Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm

    Kessler Topaz Meltzer & Check, LLP is investigating potential violations of federal securities laws by uniQure N.V. (NASDAQ: QURE) after the FDA found insufficient evidence in data for its AMT-130 gene therapy. This led to a 50% drop in uniQure's stock price. Investors with significant losses are encouraged to contact the firm for more information.

    prnewswire·
    US
    QURE
    -10.75%
    prnewswire·
    US
    QURE
    -10.75%

    UniQure's stock drops after FDA says insufficient evidence for Huntington's approval, causing plunge.

    On Thursday, UniQure stock experienced a significant decrease following news that the FDA has stated insufficient evidence for the approval of their Huntington's gene therapy. The rejection from the FDA has caused another drop in UniQure's stock, indicating a challenging situation for the company. This news emphasizes the uncertainty surrounding the fate of UniQure's treatment for Huntington's disease.

    Unusual Whales·
    US
    QURE
    -10.75%
    Unusual Whales·
    US
    QURE
    -10.75%

    Why Is UniQure Stock Falling In Pre-market?

    uniQure's stock fell 18% in pre-market trading after the FDA indicated that Phase I/II data for AMT-130 might not support a BLA submission. The company plans to request a follow-up meeting with the FDA in early 2026.

    rttnews·
    US
    QURE
    -10.75%
    rttnews·
    US
    QURE
    -10.75%

    uniQure Seeks US FDA Follow-Up Meeting After Being Told Data Do Not Support BLA Submission

    uniQure plans to urgently meet with the US FDA after being informed that phase 1/2 studies of AMT-130 data are unlikely to support a Biologics License Application. AMT-130 is a gene therapy for Huntington's disease. The company aims to meet with the FDA in Q1. uniQure's shares fell 19% in premarket trading.

    fidelity·
    US
    QURE
    -10.75%
    fidelity·
    US
    QURE
    -10.75%

    uniQure N.V. Provides Regulatory Update on AMT-130 for Huntington's Disease

    uniQure N.V. announced a regulatory update on its gene therapy AMT-130 for Huntington's disease. The FDA indicated that Phase I/II data is insufficient for BLA submission. uniQure plans to request a follow-up FDA meeting in Q1 2026. The company remains committed to advancing AMT-130 for Huntington's patients, with support from the Huntington's community highlighting the urgency of the treatment.

    TradingView·
    US
    QURE
    -10.75%
    TradingView·
    US
    QURE
    -10.75%
    © 2025 Longbridge｜Disclaimer